Analyzing Inventiva (NASDAQ:IVA) and Kiora Pharmaceuticals (NASDAQ:KPRX)

Inventiva (NASDAQ:IVA) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Inventiva and Kiora Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1	0	7	3	3.09
Kiora Pharmaceuticals	1	0	1	0	2.00

Inventiva currently has a consensus price target of $16.56, suggesting a potential upside of 248.10%. Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 282.12%. Given Kiora Pharmaceuticals’ higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Inventiva.

Valuation & Earnings

This table compares Inventiva and Kiora Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07 million	194.85	-$400.67 million	N/A	N/A
Kiora Pharmaceuticals	$16.02 million	0.72	-$10.84 million	($2.51)	-1.04

Kiora Pharmaceuticals has higher revenue and earnings than Inventiva.

Volatility and Risk

Inventiva has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500.

Institutional & Insider Ownership

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Inventiva and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Summary

Inventiva beats Kiora Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.